Arsenic trioxide-based therapy is suitable for patients with psoriasis-associated acute promyelocytic leukemia – A retrospective clinical study

Abstract

Psoriasis patients are at high risk for APL. The increased risk is most likely associated with the genetic background and bimolane treatment. The ATO-based therapy is especially suitable for patients with psoriasis-associated APL. Our study also brings a new treatment option for psoriasis.